OncoMatch/Clinical Trials/NCT06296706
A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
Is NCT06296706 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Docetaxel for and Taxotere (docetaxel) for gastric cancer.
Treatment: Docetaxel for · Taxotere (docetaxel) — This trial is a multicenter, randomized, controlled phase Ш clinical study of comparison of Docetaxel for Injection (Albumin-bound) and Taxotere in locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma with previous first-line treatment failure.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Biomarker criteria
Excluded: MMR deficient mismatch repair
Patients whose previous medical history shows dMMR/MSI-H (deficient Mismatch Repair or High Microsatellite Instability) and who have not received immunotherapy in the past are not suitable for enrollment, and those whose dMMR/MSI status is unknown need to clarify the status before enrollment.
Excluded: MSI high microsatellite instability
Patients whose previous medical history shows dMMR/MSI-H (deficient Mismatch Repair or High Microsatellite Instability) and who have not received immunotherapy in the past are not suitable for enrollment, and those whose dMMR/MSI status is unknown need to clarify the status before enrollment.
Allowed: HER2 (ERBB2) overexpression
Previous history with positive Her-2 expression requires anti-Her-2 medication; unknown Her-2 expression should define Her-2 status before enrollment.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — first-line
Cannot have received: taxane (paclitaxel, docetaxel)
Exception: disease progression more than one year after neoadjuvant/adjuvant treatment with paclitaxel/docetaxel
Lab requirements
Blood counts
Adequate main organ function.
Kidney function
Adequate main organ function.
Liver function
Adequate main organ function.
Cardiac function
No serious cardiovascular or cerebrovascular disease, including but not limited to: serious cardiac rhythm or conduction abnormalities, acute coronary syndrome, congestive heart failure, stroke, NYHA ≥ II or LVEF <50%, long QTc syndrome or QTc >480 ms, poor control of hypertension (SBP ≥ 160 mmHg and/or DBP ≥ 100 mmHg).
Adequate main organ function. History of serious cardiovascular or cerebrovascular disease, including but not limited to: ... (see exclusion criteria 6).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify